ABVC BioPharma (ABVC) Expected to Announce Earnings on Tuesday

ABVC BioPharma (NASDAQ:ABVC) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.1130 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 20, 2026 at 9:30 AM ET.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.06) EPS for the quarter.

ABVC BioPharma Price Performance

Shares of NASDAQ ABVC opened at $0.95 on Tuesday. The stock has a market cap of $25.23 million, a P/E ratio of -2.38 and a beta of 0.57. ABVC BioPharma has a 1 year low of $0.88 and a 1 year high of $3.40. The firm has a 50-day moving average of $1.33 and a 200 day moving average of $1.36.

Hedge Funds Weigh In On ABVC BioPharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new position in shares of ABVC BioPharma during the 3rd quarter valued at about $48,000. Millennium Management LLC purchased a new position in ABVC BioPharma during the third quarter valued at $60,000. Finally, Geode Capital Management LLC grew its position in shares of ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after purchasing an additional 6,017 shares in the last quarter. 11.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ABVC BioPharma has an average rating of “Sell”.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.